CYTK
Cytokinetics Inc
NASDAQ: CYTK · HEALTHCARE · BIOTECHNOLOGY
$70.15
+1.27% today
Updated 2026-06-12
Market cap
$9.52B
P/E ratio
—
P/S ratio
90.01x
EPS (TTM)
$-6.85
Dividend yield
—
52W range
$32 – $80
Volume
2.5M
Cytokinetics Inc (CYTK) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed CYTK price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$70.15
Today
Analyst consensus
$99.30
+41.55% · 12M
2030 Base
$548.13
+681.37% future
NPV today
$408.25
@ 7% WACC
22 analysts:
18 Buy3 Hold1 Sell
Management guidance
Cytokinetics has not provided explicit multi-year revenue guidance through 2030. However, CEO Robert Blum has emphasized aggressive commercialization of MYQORZO (aficamten) following positive Phase 3 data in both obstructive and non-obstructive hypertrophic cardiomyopathy (oHCM/nHCM). The company raised $805M in May 2026 specifically to fund MYQORZO commercial launch and pipeline advancement, signaling confidence in near-term revenue acceleration. Early MYQORZO revenue of $4.8M (pre-launch) and Q1 2026 revenue of $19.36M (+1,126% YoY) demonstrate that the commercial inflection has begun.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
CYTK · Cytokinetics Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$403.44
NPV today: $300.48
Base case (2030)
$548.13
NPV today: $408.25
Bull case (2030)
$1,242.63
NPV today: $925.51
WallStSmart.com
CYTK financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $0.1B | $0.3B | $0.9B | $1.4B | $1.7B | $2.0B |
| Revenue growth | 376.6% | 224.0% | 212.0% | 62.0% | 19.0% | 18.0% |
| Net margin | — | -247.0% | -32.2% | 7.6% | 20.2% | 29.0% |
| EPS | $-5.52 | $-5.20 | $-2.10 | $0.80 | $2.50 | $4.20 |
| Diluted shares | — | 135M | 136M | 137M | 138M | 139M |
| Net debt | — | $1.23B | $1.67B | $2.39B | $3.25B | $4.25B |
| P/S multiple | — | 40.0x | 40.0x | 40.0x | 40.0x | 40.0x |
| Implied price (base) | — | $75.14 | $248.88 | $402.18 | $471.80 | $548.13 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $2.0B | $2.0B | $2.0B |
| P/S multiple | 30.0x | 40.0x | 88.0x |
| Diluted shares | 139M | 139M | 139M |
| Net debt | $4.25B | $4.25B | $4.25B |
| Implied P/E † | 96x | 131x | 296x |
| 2030 Price | $403.44 | $548.13 | $1,242.63 |
| NPV @ 7% | $300.48 | $408.25 | $925.51 |
† Implied P/E: Multiples remain elevated across all three scenarios because CYTK is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $548.13 base case
CYTK catalysts and risks
Growth catalysts
+ MYQORZO commercial ramp in US (oHCM launch underway; nHCM approval expected 2026-2027)
+ EU/China MYQORZO expansion driving international revenue from 2027 onward
+ PDUFA action date November 14, 2026 for nHCM indication (catalyst for label expansion)
+ Phase 3 data for additional indications in heart failure pipeline (CK-3773274, omecamtiv mecarbil line extension)
+ Peak sales potential for MYQORZO estimated at $2B+ by peer analysts assuming broad HCM market adoption
Key risks
- MYQORZO adoption slower than modeled if payer/physician uptake lags; HCM is rare disease with small eligible population (~200K-300K in US)
- Pipeline clinical failures (heart failure programs face competitive pressure from established agents and newer startups)
- Dilution from future equity raises if operating losses persist longer than expected
- Competitive threat from Bristol Myers Squibb cardiac myosin program; BMS paused after unfavorable Phase 2 data but competitors may emerge
- Regulatory setback: LVEF drop signal (10% of aficamten vs. 1% placebo in ACACIA-HCM) may trigger post-approval risk mitigation or label restrictions
Methodology · Cytokinetics Inc 2030 stock forecast model
Cytokinetics Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 22 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (2% cumulative for CYTK by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($4.25B by 2030) |
| 3. Time value | NPV calculated using 7% WACC (CAPM: beta 0.38) |
| 4. Multiple framework | P/S compresses with scale: bear 30.0x / base 40.0x / bull 88.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
CYTK price target FAQ
What is the CYTK price target for 2030?
WallStSmart's Cytokinetics Inc 2030 base case is $548.13 per share, with a bull case of $1,242.63 and bear case of $403.44. The NPV of the base case discounted to today at 7% WACC is $408.25.
How is the Cytokinetics Inc 2030 stock forecast calculated?
The CYTK 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the CYTK price target account for dilution?
Cytokinetics Inc is projected to grow diluted share count from 136M to 139M by 2030 (a 2% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 2%.
What is the analyst consensus on CYTK stock?
22 analysts cover CYTK with an average 12-month price target of $99.30. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.